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Abstract
Importance—Tourette syndrome (TS) is characterized by high rates of psychiatric comorbidity;
however, few studies have fully characterized these comorbidities. Furthermore, most studies have
included relatively few participants (<200), and none has examined the ages of highest risk for
each TS-associated comorbidity or their etiologic relationship to TS.
Objective—To characterize the lifetime prevalence, clinical associations, ages of highest risk,
and etiology of psychiatric comorbidity among individuals with TS.

Author Manuscript

Design, Setting, and Participants—Cross-sectional structured diagnostic interviews
conducted between April 1, 1992, and December 31, 2008, of participants with TS (n = 1374) and
TS-unaffected family members (n = 1142).
Main Outcomes and Measures—Lifetime prevalence of comorbid DSM-IV-TR disorders,
their heritabilities, ages of maximal risk, and associations with symptom severity, age at onset, and
parental psychiatric history.

Author Manuscript

Results—The lifetime prevalence of any psychiatric comorbidity among individuals with TS was
85.7%; 57.7% of the population had 2 or more psychiatric disorders. The mean (SD) number of
lifetime comorbid diagnoses was 2.1 (1.6); the mean number was 0.9 (1.3) when obsessivecompulsive disorder (OCD) and attention-deficit/hyperactivity disorder (ADHD) were excluded,
and 72.1% of the individuals met the criteria for OCD or ADHD. Other disorders, including mood,
anxiety, and disruptive behavior, each occurred in approximately 30% of the participants. The age
of greatest risk for the onset of most comorbid psychiatric disorders was between 4 and 10 years,
with the exception of eating and substance use disorders, which began in adolescence
(interquartile range, 15–19 years for both). Tourette syndrome was associated with increased risk
of anxiety (odds ratio [OR], 1.4; 95% CI, 1.0–1.9; P = .04) and decreased risk of substance use
disorders (OR, 0.6; 95% CI, 0.3–0.9; P = .02) independent from comorbid OCD and ADHD;
however, high rates of mood disorders among participants with TS (29.8%) may be accounted for
by comorbid OCD (OR, 3.7; 95% CI, 2.9–4.8; P < .001). Parental history of ADHD was
associated with a higher burden of non-OCD, non-ADHD comorbid psychiatric disorders (OR,
1.86; 95% CI, 1.32–2.61; P < .001). Genetic correlations between TS and mood (RhoG, 0.47),
anxiety (RhoG, 0.35), and disruptive behavior disorders (RhoG, 0.48), may be accounted for by
ADHD and, for mood disorders, by OCD.
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Conclusions and Relevance—This study is, to our knowledge, the most comprehensive of its
kind. It confirms the belief that psychiatric comorbidities are common among individuals with TS,
demonstrates that most comorbidities begin early in life, and indicates that certain comorbidities
may be mediated by the presence of comorbid OCD or ADHD. In addition, genetic analyses
suggest that some comorbidities may be more biologically related to OCD and/or ADHD rather
than to TS.
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Introduction
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Tourette syndrome (TS) is a childhood-onset neuropsychiatric disorder characterized by
multiple motor tics and 1 or more vocal tics that persist for at least 1 year.1,2 Multiple
comorbid psychiatric disorders have been reported in TS-affected individuals; when present,
these conditions typically cause more distress and impairment than do tics.3– 7 High rates of
comorbid attention-deficit/hyperactivity disorder (ADHD) and obsessive-compulsive
disorder (OCD) have been well documented and are thought to be core components of the
TS phenotype.4,8– 11 Although elevated rates for mood disorders, nonobsessional anxiety
disorders, and disruptive behavior disorders (DBDs) have also been reported,4,12– 17 a
significant gap in knowledge still exists regarding the range, prevalence, and clinical
attributes of the non-OCD, non-ADHD comorbid disorders. The few available studies were
limited by small sample sizes (<200 participants),3,7,18–20 small number of diagnoses
examined, or reliance on symptom checklists and severity scales rather than DSM-based,
structured diagnostic psychiatric assessments.18,21– 24
Despite methodologic limitations, these studies12,13,15 suggest that a high proportion of
individuals with TS (61%–96%) have at least 1 comorbid psychiatric disorder.
Unfortunately, there is no consensus regarding expected rates of the noncore (ie, non-OCD,
non-ADHD) psychiatric disorders in TS-affected individuals; in addition, there is limited
knowledge regarding typical age at onset, ages of highest risk, and association with
impairment for these disorders.

Author Manuscript

Although the shared genetic susceptibility to OCD and ADHD in TS-affected families has
been established,25– 27 the etiologic relationships between TS and other psychiatric disorders
have not been examined. Elevated rates of psychiatric comorbidity may arise from (1)
shared genetic susceptibility with TS, (2) shared genetic susceptibility with comorbid OCD
or ADHD, or (3) nongenetic factors (eg, shared environment). Together with quantifying the
extent of concomitant occurrence, understanding the clinical and etiologic relationships
between TS, OCD, ADHD, and other psychiatric comorbidities will help in understanding
the sources of heterogeneity of this complex neuropsychiatric disorder. Therefore, the aims
of the present study were to quantify psychiatric disorder burden, ages of highest risk, and
underlying genetic relationship of psychiatric disorders in TS-affected individuals using the
largest, most comprehensive data set available.

Methods

Author Manuscript

The study was described to all participants; adults provided written informed consent and
children written assent before participating. Parents provided written consent for their
children’s participation. Institutional review board approval was obtained from all
participating sites. The participants did not receive financial compensation. The eAppendix
in the Supplement includes the inclusion and exclusion criteria and informed consent details.
Participants
Phenotypic data were collected for genetic studies from TS-affected individuals aged 6 years
or older and their parents and siblings, ascertained from 802 independent families between

JAMA Psychiatry. Author manuscript; available in PMC 2015 May 27.
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April 1, 1992, and December 31, 2008. Recruitment primarily occurred from tic disorder
specialty clinics in the United States, Canada, Great Britain, and the Netherlands as well as
from the Tourette Syndrome Association of the United States.
Phenotypic Assessments

Author Manuscript

A psychiatrist, neurologist, or psychologist trained in the use of clinical research
assessments evaluated all participants (D.L.P., Y.D., M.A.G., C.I., R.A.K., P.S., W.M.M.,
D.C.C., R.K., M.M.R., and C.A.M.).28 Tics, OCD, and ADHD symptoms were assessed
using a structured clinical interview specifically developed for TS genetic studies
(eAppendix in the Supplement). The Structured Clinical Interview for DSM-IV Axis I
Disorders–Non-Patient Edition, 2.029 (all sites except the University of Utah site) or the
Schedule for Affective Disorders and Schizophrenia–Lifetime Version, Modified for the
Study of Anxiety Disorders30 (University of Utah site) was used to gather data on DSM-IVTR diagnoses for adults. The Schedule for Affective Disorders and Schizophrenia for
School-Age Children, the Lifetime Version31 (all sites except Johns Hopkins University
School of Medicine or University of Toronto) or the Epidemiologic Version32 (Johns
Hopkins University School of Medicine and University of Toronto sites) was used to collect
data on DSM-IV-TR diagnoses in children and adolescents. Final diagnoses were assigned
using a best-estimate process, which requires diagnostic consensus by at least 2 raters.28,33
We grouped individual disorders into DSM-IV-TR–based categories (eg, anxiety disorders)
to aid in clinical interpretation. The eAppendix in the Supplement includes details regarding
diagnostic instruments, rater training and reliability, age-at-onset determination, and the
best-estimate process.
Statistical Analysis

Author Manuscript
Author Manuscript

For lifetime prevalence estimates of comorbid disorders and ages at onset, we limited the
sample to the 1374 participants with TS. We also examined the lifetime prevalence of
disorders among probands compared with their TS-affected first-degree relatives
(eAppendix in the Supplement). To examine the association among TS, OCD, and ADHD
with other comorbid disorders and for heritability analyses, we included all individuals,
including TS-unaffected family members. We compared the rates of comorbid disorders by
sex and age at interview using χ2 and Fisher exact tests. We examined the relationship
between psychiatric comorbidity and TS, OCD, and ADHD by comparing lifetime
prevalence rates of comorbid disorders among participants with TS only, TS and OCD only
(TS+OCD), TS and ADHD only (TS+ADHD), and TS with both OCD and ADHD (TS
+OCD+ADHD) using χ2 tests. We used generalized estimating equations to examine the
association of TS, ADHD, and OCD (individually and in combination) with other comorbid
disorders, controlling for family relationships, age at interview, and sex.
For each disorder, we graphed the number of individuals with each age at onset using violin
plots along with the median value and corresponding interquartile range. Age of highest risk
was defined as the age at which the cumulative risk exceeded 10% (lower bound) through
the upper bound of the interquartile range.

JAMA Psychiatry. Author manuscript; available in PMC 2015 May 27.
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Using generalized estimating equation models clustering on family and controlling for age at
interview and sex, we tested the association between the presence of 1 or more comorbid
disorder (excluding OCD and ADHD) with OCD and tic severity; OCD and ADHD;
parental history of OCD, ADHD, and TS; and TS, OCD, and ADHD ages at onset. To
improve clinical interpretation, we transformed continuous severity measures into 3
categories (low, medium, and high) and ages at onset into early and late onset so that there
were approximately equal numbers of participants in each group. Variables from each
generalized estimating equation model with a significance level of P ≤ .20 were added
simultaneously to a multivariate model.
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We calculated the additive genetic and environmental correlations between TS and classes
of comorbid disorders using the Sequential Oligogenic Linkage Analysis Routines (SOLAR,
version 6.2.2)34 (eAppendix and eFigure in the Supplement). For these analyses, TS was
combined with chronic motor or vocal tic disorders (CMVTDs). We did not examine the
heritability of psychotic or eating disorders because of the low prevalence rates or of
elimination disorders because of missing parental data.

Results
Demographic Characteristics

Author Manuscript

The sample consisted of 1374 TS-affected individuals, including parents or siblings without
a TS diagnosis who met the best estimate criteria for TS (583 [42.4%]), and 1142 TSunaffected first-degree relatives. The subsample of TS-affected individuals showed a 3:1
male predominance (1006 [73.2%] male), and the mean (SD) age at assessment was 19.1
(13.5) years. Demographics and clinical characteristics of TS-affected and TS-unaffected
participants are presented in eTable 1 in the Supplement.
Overall Burden of Psychiatric Comorbidity

Author Manuscript

Of the participants with TS, 85.7% met the criteria for 1 or more comorbid disorder
(including OCD and ADHD) and 57.7% met the criteria for 2 or more comorbid disorders.
Lifetime prevalence rates for classes of comorbid disorders are summarized in Table 1; rates
of individual disorders by sex and age are presented in eTable 2 and eTable 3, respectively,
in the Supplement. The mean (SD) number of lifetime disorders was 2.1 (1.6). When OCD
and ADHD were excluded, 45.3% of the patients met the criteria for 1 or more comorbid
disorder and 23.6% met the criteria for 2 or more comorbid disorders. The mean number of
lifetime diagnoses, excluding OCD and ADHD, was 0.9 (1.3). There were no significant
differences in the rates of comorbid diagnoses between probands and TS-affected relatives
when controlling for age at assessment (eTable 4 in the Supplement); therefore, subsequent
analyses combined these groups.
Prevalence of Specific Psychiatric Disorders
OCD and ADHD—The most common comorbid psychiatric disorders were OCD (50.0%)
and ADHD (54.3%); 72.1% of the TS-affected participants met the criteria for either
disorder. Females were more likely to have comorbid OCD (57.1% vs 47.5%; P < .01), and
males were more likely to have comorbid ADHD (58.5% vs 42.3%; P < .01). Nearly one-

JAMA Psychiatry. Author manuscript; available in PMC 2015 May 27.

Hirschtritt et al.

Page 6

Author Manuscript

third (29.5%) of the participants had TS+OCD+ADHD, 20.2% had TS+OCD, 22.4% had TS
+ADHD, and 27.9% had TS only. There was a significant interaction of sex and age with
diagnostic group (χ2 = 43.1, P < .001; and χ2 = 121.6, P < .001, respectively).

Author Manuscript

Other Conditions—After OCD and ADHD, mood disorders, anxiety disorders, and
DBDs were the most prevalent classes of psychiatric comorbidity, each affecting
approximately 30% of TS-affected participants; psychotic disorders were the least common
(<1%). The prevalence of individual disorders ranged from 0.5% (bipolar II disorder) to
26.1% (major depressive disorder) (eTables 2–5 in the Supplement). Females were more
likely to have major depressive disorder, most anxiety disorders, and eating disorders. Males
were more likely to have ADHD and DBD (oppositional defiant disorder or conduct
disorder) (Table 1 and eTable 2 in the Supplement). Adults and adolescents were most likely
to have OCD as well as mood, anxiety, eating, and substance use disorders, whereas
children were more likely to have ADHD (eTable 3 in the Supplement).
There was a clear relationship between OCD, ADHD, and the other psychiatric
comorbidities in TS-affected participants. Mood, anxiety, and substance use disorders were
more prevalent among participants with TS+OCD and TS+OCD+ADHD than among those
with TS-only or TS+ADHD. Disruptive behavior disorders and psychotic disorders were
more prevalent among participants with TS+OCD+ADHD than among the other 3 groups
(Figure 1 and eTable 5 in the Supplement). When these analyses were repeated for males
and females separately using the diagnostic groups shown in Figure 1, patterns of
significance for χ2 analyses were comparable to those for all TS-affected participants
combined, except for psychotic disorders, which is attributable to small sample sizes (eTable
5 in the Supplement).
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To assess the relationships between TS, OCD, ADHD, and psychiatric comorbidity, we
conducted a multivariate generalized estimating equation model in all individuals (eTable 6
in the Supplement). After controlling for OCD and ADHD, TS was independently
associated with an increased risk of anxiety disorders (odds ratio [OR], 1.4; 95% CI, 1.0–
1.9; P = .04) and a decreased risk of substance use disorder (OR, 0.6; 95% CI, 0.3–0.9; P = .
02); there was no significant independent association between TS and mood disorder or
DBD. Obsessive-compulsive disorder was independently associated with a 2-fold or greater
risk of mood disorders (OR, 3.8; 95% CI, 2.9–4.9; P < .001), anxiety disorders (OR, 2.8;
95% CI, 2.2–3.6; P < .001), DBDs (OR, 2.0; 95% CI, 1.4–2.9; P < .001), and substance use
disorders (OR, 3.9; 95% CI, 2.5–6.0; P < .001). Attention-deficit/hyperactivity disorder was
independently associated with an increased risk of anxiety disorders (OR, 1.5; 95% CI, 1.2–
2.0; P < .01) and DBDs (OR, 4.0; 95% CI, 2.6–6.2; P < .001) but not substance use or mood
disorders. There were no significant associations between TS, OCD, ADHD, and
elimination or eating disorders. The results of these models build on those summarized in
Figure 1 because they control for the age and sex of the participants.
Age of Highest Risk—The median age at onset for TS was 6 years (interquartile range,
4–8 years) (Figure 2 and eTable 7 in the Supplement). Attention-deficit/hyperactivity
disorder and DBD had the youngest median age at onset and earliest ages of highest risk (5
years: interquartile ranges, 3–6 and 3–8, respectively). The high-risk period began at age 4
JAMA Psychiatry. Author manuscript; available in PMC 2015 May 27.
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years for anxiety disorders, 7 years for mood disorders, and 13 years for substance use and
eating disorders. Compared with males, females tended to have later ages at onset of TS,
DBDs, anxiety disorders, and mood disorders (eTable 7 in the Supplement).
Clinical Correlates of Number of Psychiatric Disorders
High tic and moderate/high OCD symptom severity, lifetime prevalence of ADHD or OCD,
and parental history of TS/CMVTD and ADHD were associated with having 1 or more
noncore psychiatric comorbidity in univariate analyses (Table 2). In the multivariate model,
only high tic severity (OR, 1.57; 95% CI, 1.11–2.21; P = .01), ADHD (OR, 1.51; 95% CI,
1.12–2.03; P < .01), OCD (OR, 1.77; 95% CI, 1.34–2.35; P < .001), and parental history of
ADHD (OR, 1.55; 95% CI, 1.08–2.23; P = .02) remained significant. Obsessive-compulsive
disorder severity was omitted from the multivariate model to avoid confounding with OCD
diagnosis.

Author Manuscript

Genetic Relationships With TS
Consistent with previous findings,26,35 including those from a subset of the current sample,
TS/CMVTD, OCD, and ADHD all demonstrated significant genetic correlations (eTable 8
in the Supplement). In addition, TS/CMVTD had significant genetic correlations with mood
disorders (RhoG [SE], 0.47 [0.17]; P = .004), anxiety disorders (RhoG [SE], 0.35 [0.15]; P
= .02), and DBDs (RhoG [SE], 0.40 [0.18]; P = .02); these correlations were not significant
when controlling for OCD and ADHD (eTable 9 in the Supplement). Mood disorders,
anxiety disorders, and DBDs were also genetically correlated with ADHD; these
correlations remained significant after controlling for TS/CMVTD and OCD (Table 3).
Furthermore, mood disorders were significantly genetically correlated with OCD, even
when controlling for TS/CMVTD and ADHD (Table 3).

Author Manuscript

Discussion
This study represents the most comprehensive examination to date of the extent and burden
of comorbid psychiatric disorders in TS, and is the first to report ages of highest risk and
etiological relationships with TS for a wide variety of psychiatric conditions. Our results
have implications both clinically and for ongoing research into the causes and etiological
relationships between these psychiatric disorders.
Clinical relevance

Author Manuscript

Consistent with previous studies3,4,12,15,36–39, we identified a very high burden of
psychiatric disorders. Our results suggest that the vast majority of children with TS can be
expected to develop ≥1 comorbid psychiatric disorder over their lifetime, and more than half
will develop two. In addition to high rates of OCD (50.0%) and ADHD (54.3%), we also
found high rates of mood (29.8%), anxiety (36.1%), DBD (29.7%), and elimination
disorders (16.2%). We found relatively low rates of psychotic disorders and substance abuse
at the time of evaluation, although we do not have longitudinal data later on in life for the
younger individuals, when such disorders typically manifest.

JAMA Psychiatry. Author manuscript; available in PMC 2015 May 27.
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Importantly, this study is the first to report ages of highest risk for comorbid psychiatric
disorders, as well as the relationship of demographic and clinical characteristics with overall
disorder burden in TS. For most disorders, the age of greatest risk began before age 5, with
high risk for anxiety and DBD continuing into adolescence, and risk for depressive disorders
continuing into young adulthood. Previous research has demonstrated that TS symptoms
typically emerge between the ages of 5 and 7 years13,40, while ADHD generally appears 2 to
3 years earlier41, and OCD 5 to 6 years later42. In this study, DBD and ADHD began at or
before age 5, prior to tic onset. In contrast to population-based epidemiologic studies43,44,
OCD and anxiety disorders also began early, typically within a year of onset of tics (with
many cases beginning earlier); mood disorders had a more distributed age-of-onset pattern,
beginning as early as age 5, and becoming more frequent around ages 7–8. These results, in
combination with the high likelihood of developing a mood, anxiety, or DBD, suggest that
psychiatric assessments of TS-affected children should begin early and continue throughout
adolescence and adulthood.
Our results also suggest that TS-affected children who also have OCD or a parent with
ADHD in particular should be carefully evaluated over time for the development of mood,
anxiety, and DBD, and adolescents, particularly those with OCD and/or ADHD, should also
be monitored for the development of a substance use disorder. Similarly, TS-affected
children with ADHD should be evaluated for other DBD and anxiety disorders. The
association between high tic severity and the number of non-ADHD/non-OCD
comorbidities is consistent with a previous study demonstrating an association between tic
severity and non-OCD anxiety disorders12.
Etiological relevance
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The heritability estimates confirm previous research26,35 showing that TS, OCD, and ADHD
are highly genetically related. However, for the first time, we also provide evidence of a
strong genetic relationship between these TS-related phenotypes and mood, anxiety, and
DBD. Of particular interest, our analyses suggest that the observed genetic correlations
between TS and these disorders are better accounted for by an underlying genetic
relationship with ADHD and, in the case of mood disorders, by an underlying genetic
relationship with both ADHD and OCD. In non-TS samples, there is considerable
evidence45 to support shared genetic variance between ADHD and DBD, and some data46 to
support a shared genetic diathesis underlying ADHD and major depressive disorder. Genetic
relationships between OCD and mood disorders have not previously been examined. Our
findings are in line with a previous study that found no increased rates of ADHD47 or other
non-OCD disorders such as anxiety, affective, substance abuse and psychotic disorders,48
among parents of probands with TS compared to controls, suggesting that these disorders
segregate independently from TS. Our findings that parental history of ADHD predicts
psychiatric disorder burden in TS-affected offspring, independent of parental history of TS
and OCD, provides additional support for the observed genetic relationships between
psychiatric disorders and ADHD.
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Hirschtritt et al.

Page 9

Limitations

Author Manuscript
Author Manuscript

This study has several limitations. First, our data are cross-sectional, thus, we cannot assess
causation (e.g., whether clinical characteristics predicted subsequent disorder onset).
Second, the predominately clinic-based recruitment may have biased our sample to
participants with more severe, comorbid, or familial TS, limiting generalizability. This
concern is somewhat mitigated by the presence of parents and previously undiagnosed
siblings with TS, who were typically less severely affected. Third, although consistent with
previous studies, the total psychiatric burden identified is likely an underestimate, given that
some disorders were not assessed (e.g., pervasive developmental disorders [PDDs]) and not
everyone had passed the age of risk for all disorders. Specifically, parents were not routinely
assessed for certain childhood disorders (e.g., elimination disorders) and children were not
assessed for schizophrenia, although they were assessed for psychosis. Similarly, the
lifetime rates of schizophrenia, bipolar disorder, and substance use disorders could be
attenuated by an ascertainment bias (i.e., the children and adolescents in our sample may
have developed these adult-onset disorders later in life). Fourth, ADHD severity was not
uniformly assessed. Fifth, we did not have reliable data regarding recruitment method (i.e.,
TSA vs. specialty clinics), and characteristics of participants may vary by recruitment
method. Sixth, PDDs were not systematically assessed or uniformly excluded; future studies
should examine patterns of comorbidity between TS and PDDs49. Finally, because the
parent genetic study focused on sibling pairs and parent-child trios, the heritabilities may be
underestimates, as the algorithm employed by SOLAR is best suited to analysis of
multigenerational families.
Conclusions
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This study provides important new data regarding the prevalence, predictors, and ages of
highest risk for psychiatric illness among individuals affected with TS, as well as for the
first time formally evaluating the etiological relationships between disorders other than OCD
and ADHD. The key clinical findings, that mood, anxiety, and DBD are very common
among TS-affected individuals, tend to begin early in life, and are highly associated with
comorbid OCD and ADHD, are of direct and immediate relevance for practitioners. The
genetic analyses advance our understanding of the etiological relationships between TS and
other psychiatric disorders, and provide a framework for future studies aimed at better
understanding the biology of these complex, inter-related syndromes.
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Figure 1.

Lifetime Prevalence of Comorbid Disorders by Presence of OCD and ADHD Among
Individuals with Tourette Syndrome. Significance values reflect individual 4-by-2 χ2 tests
(i.e., TS/OCD/ADHD group by presence of the comorbid disorder).
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Figure 2.

Ages-of-Onset for Comorbid Disorders Among Individuals with Tourette Syndrome. Points
and bars represent median ages-of-onset and interquartile ranges, respectively. Width of
each plot is proportional to the number of individuals with the given age of onset.
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Author Manuscript

Lifetime Prevalence of Psychiatric Disorders by Sex
Comorbid disorder

Sex

Author Manuscript

All TS-affected
participants
n/total with available
data (%)

Male
n/total with available
data (%)

Female
n/total with available
data (%)

p-value

Obsessive compulsive spectrum disorders a

904/1368 (66.1)

645/1001 (64.4)

259/367 (70.6)

.03

Attention-deficit/hyperactivity disorder

713/1314 (54.3)

564/962 (58.6)

149/352 (42.3)

< .001

Mood disorders b

277/930 (29.8)

184/690 (26.7)

93/240 (38.8)

< .001

Anxiety disorders c

343/949 (36.1)

225/703 (32.0)

118/246 (48.0)

< .001

Disruptive behavior disorders d

185/622 (29.7)

157/493 (31.9)

28/129 (21.7)

.03

Eating disorders e

19/937 (2.0)

2/693 (0.3)

17/244 (7.0)

< .001

Psychotic disorders f

7/931 (0.8)

5/689 (0.7)

2/242 (0.8)

.88

Substance use disorders g

59/948 (6.2)

42/701 (6.0)

17/247 (6.9)

.62

Elimination disorders h

108/668 (16.2)

90/531 (17.0)

18/137 (13.1)

.28

Chi-squared or Fisher’s exact test were used to compare rates of each disorder in males vs females.
a

Includes: obsessive-compulsive disorder and subclinical obsessive-compulsive disorder,

b

major-depressive disorder, dysthymia, and bipolar disorder I and II,

c
generalized anxiety disorder, panic disorder, agoraphobia without panic, posttraumatic stress disorder, separation anxiety disorder, social phobia,
and specific phobia,
d

oppositional-defiant and conduct disorders,

e

Author Manuscript

anorexia and bulimia nervosa,

f

schizophrenia and psychotic disorder, not otherwise specified,

g

alcohol and other substance use or dependence, excluding tobacco use, and

h

enuresis and encopresis.
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Table 2

Author Manuscript

Clinical Predictors of Having ≥ 1 Comorbid Disorder, Excluding OCD and ADHD
Characteristic (reference value)

Levels

OR (95% CI)

p-values

17–21

1.18 (0.90—1.55)

.24

22–30

1.87 (1.43—2.46)

<.001

3–6

1.64 (1.26—2.13)

<.001

7–12

2.86 (2.13—3.82)

<.001

  ADHD (no ADHD)

ADHD present

1.93 (1.53—2.43)

<.001

  OCD (no OCD)

OCD present

2.17 (1.75—2.70)

<.001

  Parental history of TS/CMVTD (parental TS/CMVTD absent)

Parental TS/CMVTD present

1.33 (1.01—1.76)

.04

  Parental history of OCD (parental OCD absent)

Parental OCD present

1.11 (0.84—1.47)

.46

  Parental history of ADHD (parental ADHD absent)

Parental ADHD present

1.86 (1.32—2.61)

<.001

  TS age of onset (≥7 y)

<7y

1.02 (0.82—1.29)

.84

  OCD age of onset (≥8 y)

<8y

1.10 (0.74—1.64)

.63

  ADHD age of onset (≥ 5 y)

<5y

1.35 (0.90—2.01)

.14

Symptom severity a
  Tic severity tertiles (0–16)

  OCD severity tertiles (0–2)
Comorbid conditions

Parental history b

Author Manuscript

Age of onset

Separate generalized estimating equations, clustering on family and controlling for age at interview and sex, were modeled with the presence of ≥ 1
comorbid disorder, other than ADHD or OCD, as the outcome and each clinical characteristic as the predictor variable.
a

Symptom severity scales for tics and obsessive-compulsive symptoms are described in the Supplemental Methods.

b

Parental history only available for probands and their full siblings.

Author Manuscript

ADHD, attention-deficit/hyperactivity disorder; CMVTD, chronic motor or vocal tic disorder; OCD, obsessive-compulsive disorder; TS, Tourette
syndrome

Author Manuscript
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.59
(.12)

.68
(.15)

.59
(.13)

.40
(.12)

Anxiety

Disruptive
behavior

Mood

Anxiety

Disruptive
behavior

.77
(.14)

Mood

.34
(.13)

.55
(.11)

2.7 × 10−3

4.2 × 10−6

.53
(.15)

.34
(.11)

3.5 × 10−5

3.2 × 10−3

.66
(.16)

.74
(.15)

1.9 × 10−5

2.6 × 10−2

RhoG
(SE)

.54
(.13)

−.32
(.14)

1.6 × 10−8

RhoE pvalue

3.2 × 10−6

RhoE
(SE)

RhoG pvalue

.02

1.1 × 10−3

6.9 × 10−5

5.0 × 10−5

3.9 × 10−7

RhoG pvalue

.55
(.11)

.40
(.11)

.31
(.15)

RhoE
(SE)

1.2 × 10−5

7.2 × 10−4

.03

RhoE pvalue

.47
(.17)

.62
(.17)

.40
(.15)

.68
(.18)

RhoG
(SE)

.01

5.3 × 10−4

7.7 × 10−3

8.6 × 10−5

RhoG pvalue

.60
(.10)

.43
(.10)

−.29
(.14)

RhoE
(SE)

2.4 ×
10−7

1.3 ×
10−4

.04

RhoE
p-value

Covarying for OCD or ADHD a, b

.41
(.18)

.61
(.17)

.43
(.14)

.70
(.18)

RhoG
(SE)

.04

6.2 × 10−4

3.2 × 10−3

2.3 × 10−5

RhoG pvalue

.62
(.11)

.48
(.11)

−.36
(.15)

RhoE
(SE)

3.6 × 10−7

3.8 × 10−5

.02

RhoE pvalue

Covarying for TS and OCD or ADHD a, b

ADHD, attention-deficit/hyperactivity disorder; OCD, obsessive-compulsive disorder; TS/CMVTD, Tourette syndrome/chronic motor and vocal tic disorder

In bivariate analyses with ADHD, OCD (not ADHD) was included as a covariate; conversely, in bivariate analyses with OCD, ADHD (not OCD) was included as a covariate.

b

All analyses include sex, age, and sex-by-age as covariates.

a

Genetic and environmental correlation (RhoG and RhoE, respectively) between TS/CMVTD and groups of comorbid disorders were estimated; where RhoG was significant, ADHD and OCD were added separately as covariates to assess the independent association between TS/
CMVTD and the given comorbid disorders. Subsequently, a series of bivariate analyses with ADHD and OCD were conducted for disorders with a significant RhoG with TS to determine the unique contributions of ADHD and OCD to the genetic correlation between TS and
each of these disorders (mood, anxiety, and disruptive behavior disorders). Blank cells represent non-significant correlations (i.e., p>0.5).

Bivariate
heritability
with OCD

Bivariate
heritability
with ADHD

RhoG
(SE)

Comorbid
disorder

Covarying for TS a

Author Manuscript

No additional diagnostic covariates a

Author Manuscript

Bivariate Heritability of Comorbid Diagnoses with TS/CMVTD, OCD, and ADHD
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